• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺苷与硝苯地平对肺动脉高压的疗效比较。

Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.

作者信息

Schrader B J, Inbar S, Kaufmann L, Vestal R E, Rich S

机构信息

Department of Pharmacy Practice, University of Illinois, Chicago.

出版信息

J Am Coll Cardiol. 1992 Apr;19(5):1060-4. doi: 10.1016/0735-1097(92)90295-x.

DOI:10.1016/0735-1097(92)90295-x
PMID:1552096
Abstract

The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension. All patients were given adenosine, 50 micrograms/kg per min, increased by 50 micrograms/kg per min at 2 min intervals to a maximum of 500 micrograms/kg per min or until the development of untoward side effects. The patients were then given oral nifedipine, 20 mg every hour, until a greater than or equal to 20% decrease in pulmonary vascular resistance or systemic hypotension occurred. The administration of maximal doses of adenosine, 256 +/- 46 micrograms/kg per min, produced a 2.4% reduction in pulmonary artery pressure (p = NS), a 37% decrease in pulmonary vascular resistance (p less than 0.001) and a 57% increase in cardiac index (p less than 0.001). The administration of maximally effective doses of nifedipine (91 +/- 36 mg) produced a 15% reduction in the mean pulmonary artery pressure (p less than 0.05), a 24% decrease in pulmonary vascular resistance (p less than 0.01) and an 8% increase in cardiac index (p = NS). There was a significant correlation (r = 0.714, p = 0.01) between the reduction in pulmonary vascular resistance that resulted from adenosine administration and that achieved with the administration of nifedipine. Six patients had substantial reductions in pulmonary vascular resistance with adenosine but not with nifedipine. Thus, adenosine is an effective vasodilator in patients with pulmonary hypertension and can be used for safe and rapid assessment of vasodilator reserve in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对15例肺动脉高压患者研究了静脉注射强效血管扩张剂腺苷的血流动力学效应。所有患者均给予腺苷,起始剂量为50微克/千克每分钟,每2分钟增加50微克/千克每分钟,最大剂量至500微克/千克每分钟或直至出现不良反应。然后患者每小时口服硝苯地平20毫克,直至肺血管阻力降低大于或等于20%或出现系统性低血压。静脉注射最大剂量腺苷(256±46微克/千克每分钟)可使肺动脉压降低2.4%(p=无显著性差异),肺血管阻力降低37%(p<0.001),心脏指数增加57%(p<0.001)。口服最大有效剂量硝苯地平(91±36毫克)可使平均肺动脉压降低15%(p<0.05),肺血管阻力降低24%(p<0.01),心脏指数增加8%(p=无显著性差异)。腺苷给药后肺血管阻力的降低与硝苯地平给药后肺血管阻力的降低之间存在显著相关性(r=0.714,p=0.01)。6例患者使用腺苷后肺血管阻力显著降低,但使用硝苯地平后未降低。因此,腺苷对肺动脉高压患者是一种有效的血管扩张剂,可用于安全、快速评估这些患者的血管扩张储备。(摘要截短至250字)

相似文献

1
Comparison of the effects of adenosine and nifedipine in pulmonary hypertension.腺苷与硝苯地平对肺动脉高压的疗效比较。
J Am Coll Cardiol. 1992 Apr;19(5):1060-4. doi: 10.1016/0735-1097(92)90295-x.
2
Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.
Am J Cardiol. 1983 Jan 1;51(1):195-200. doi: 10.1016/s0002-9149(83)80035-6.
3
Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.腺苷联合钙通道阻滞剂对原发性肺动脉高压患者的影响。
J Am Coll Cardiol. 1993 Feb;21(2):413-8. doi: 10.1016/0735-1097(93)90683-r.
4
Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension.硝苯地平对支气管肺发育不良和肺动脉高压婴儿的急性血流动力学影响。
Pediatr Res. 1988 Aug;24(2):186-90. doi: 10.1203/00006450-198808000-00009.
5
Effects of dopamine and nifedipine infusions on the pulmonary circulation of the lamb.多巴胺和硝苯地平输注对羔羊肺循环的影响。
Pediatr Pharmacol (New York). 1986;5(4):261-71.
6
Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease.硝苯地平对与弥漫性系统性硬化症、CREST综合征及混合性结缔组织病相关的肺动脉高压患者肺循环和体循环血流动力学的急性及长期影响
Am J Cardiol. 1991 Dec 15;68(17):1687-91. doi: 10.1016/0002-9149(91)90330-n.
7
Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.
Chest. 1986 Apr;89(4):497-503. doi: 10.1378/chest.89.4.497.
8
Adenosine as a vasodilator in primary pulmonary hypertension.腺苷作为原发性肺动脉高压中的一种血管扩张剂。
Circulation. 1991 Sep;84(3):1145-9. doi: 10.1161/01.cir.84.3.1145.
9
Hemodynamic effects of nifedipine on secondary pulmonary hypertension in man.硝苯地平对人类继发性肺动脉高压的血流动力学影响。
Acta Cardiol. 1985;40(2):207-15.
10
High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.钙通道阻滞剂高剂量滴定用于原发性肺动脉高压:短期药物测试指南
J Am Coll Cardiol. 1991 Nov 1;18(5):1323-7. doi: 10.1016/0735-1097(91)90556-o.

引用本文的文献

1
Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension.慢性高剂量钙通道阻滞剂暴露于肺动脉高压儿童中的安全性。
Front Cardiovasc Med. 2022 Sep 7;9:918735. doi: 10.3389/fcvm.2022.918735. eCollection 2022.
2
2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.2014年台湾心脏病学会(TSOC)肺动脉高压管理指南。
Acta Cardiol Sin. 2014 Sep;30(5):401-44.
3
Timed response to inhaled nitric oxide in pulmonary hypertension.肺动脉高压患者对吸入一氧化氮的定时反应。
Pulm Circ. 2014 Mar;4(1):103-9. doi: 10.1086/674880.
4
Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension.社会经济地位较低与肺动脉高压的预后较差相关。
Am J Respir Crit Care Med. 2013 Feb 1;187(3):303-10. doi: 10.1164/rccm.201207-1290OC. Epub 2012 Dec 6.
5
The value of tools to assess pulmonary arterial hypertension.评估肺动脉高压的工具的价值。
Eur Respir Rev. 2011 Dec;20(122):222-35. doi: 10.1183/09059180.00006911.
6
Overview of current therapeutic approaches for pulmonary hypertension.肺动脉高压的当前治疗方法概述。
Pulm Circ. 2011 Apr-Jun;1(2):138-59. doi: 10.4103/2045-8932.83444.
7
Recognition and management of pulmonary hypertension.肺动脉高压的识别与管理。
Drugs. 1998 Dec;56(6):989-1007. doi: 10.2165/00003495-199856060-00004.